CRIP1 potentially regulates age- and sex-dependent inflammation and metabolism, linking it to male susceptibility to metabolic syndrome and CVD, and highlighting it as a potential target for sex-specific therapies.
Abstract
Cardiovascular disease (CVD) is one of the leading causes of death worldwide. Metabolic syndrome (MetS) with subacute, low-grade inflammation, obesity, dyslipidemia, hypertension and peripheral insulin resistance or type 2 diabetes mellitus (T2DM) is a major risk factor for many CVD. The incidence of MetS often parallels the incidence of obesity and type 2 diabetes and the prevalence increases with age. In obesity, adipose tissue and immune cells secrete proinflammatory molecules disrupting metabolic regulation. Transcriptome analysis of human monocytes by our group identified CRIP1 as a gene significantly associated with blood pressure.
This study aims to evaluate whether and to what extent CRIP1 influences the risk of developing metabolic syndrome (MetS) and cardiovascular disease (CVD), with a particular focus on sex-specific differences.
Monocytic CRIP1 expression and metabolic risk factors were analysed in 1,527 Gutenberg-Health-Study (GHS) participants. In a prediabetic mouse model, white adipose tissue inflammation markers and Crip1 were measured by qPCR. CRIP1 was downregulated in human monocytes via shRNA, followed by pro-inflammatory stimulation; cytokines were assessed by ELISA and qPCR. Bone marrow cells from Crip1-KO mice were differentiated into monocytes to validate human in vitro findings. Crip1-KO mice were treated with Angiotensin II (AngII) for 7 days, PBMCs were isolated, and single-cell RNA sequencing performed. In aged WT and Crip1-KO mice, insulin and glucose were measured by ELISA and glucometer.
Monocytic CRIP1 expression increased steadily between 30 and 80 years and correlated with age (R² = 0.058; p = 2.31×10⁻²⁰) in 1,527 GHS participants. Furthermore, CRIP1 associated with BMI and HbA1c, but only in male individuals. Mice fed a Western diet for 20 weeks exhibited weight gain, increased white adipose tissue inflammation (Ccl2, Tnf), and elevated Crip1 gene expression, which was observed only in males. CRIP1 downregulation in LPS-stimulated monocytic cell lines reduced NLRP3 inflammasome activation and IL-1B, IL-18, TNF, and IL6 levels. Bone-marrow-derived monocytes from male Crip1-KO mice confirmed these findings. RNA-seq of PBMCs following 7 days of AngII treatment revealed a robust transcriptional response in WT mice, whereas Crip1-KO male mice displayed elevated basal expression of inflammatory genes that were largely downregulated after AngII, indicating a dampened proinflammatory response. In aged mice (70–80 weeks), male Crip1-KO mice weighed less than WT controls, with no differences in insulin or glucose levels.
CRIP1 potentially regulates age- and sex-dependent inflammation and metabolism, linking it to male susceptibility to metabolic syndrome and CVD, and highlighting it as a potential target for sex-specific therapies.
Type 2 diabetes mellitus (T2DM) is a major metabolic disorder characterized by insulin resistance, progressive β-cell dysfunction, chronic hyperglycemia, and a high burden of cardiovascular disease (CVD). Increasing evidence indicates that adipose tissue is an endocrine organ whose secretory products, or adipokines, pa...
Abdulhakim Erian Mustafa Wazeery, Abdelrahman A. Elsaied, H. E. Mahmoud et al.· Adolescência e Saúde· 0 citations
A collection of metabolic disorders, such as central obesity, insulin resistance, hypertension, and dyslipidemia, are known as metabolic syndrome. Together, these variables raise the risk of atherosclerosis, type II diabetes, and cardiovascular illnesses. The prevalence of MetS is rising globally, especially in populat...
D. A. Kadhim· Journal of Biomedicine and B...· 0 citations
In a real-world cohort from primary care/endocrinology clinics, the prevalence of MASLD increased in a stepwise manner with glycaemic and BMI categories, but the prevalence of fibrosis did not increase in the same stepwise manner and remained rare in the absence of obesity, or in obesity without significant insulin res...
Eddison Godinez Leiva, Diana Barb, S. Kalavalapalli et al.· Diabetologia· 0 citations
Introduction: Cardiometabolic diseases (CMD) are a group of interconnected metabolic and cardiovascular disorders influenced by genetic, environmental, and lifestyle factors, representing a major cause of global mortality [1]. Metabolic dysfunctions such as obesity, type 2 diabetes, and dyslipidemia contribute to vascu...
S. Adnan, Tisa Shah, Rahaf Zeidan· Undergraduate Research in Na...· 0 citations
Cardiometabolic diseases such as type 2 diabetes, hypertension, dyslipidemia, and cerebrovascular disease, are among the leading causes of mortality in Latin America, with a significant impact on the female population. In Mexico, these conditions show a high and increasing prevalence, particularly among postmenopausal...
M. L. Basurto-Acevedo, A. De la Peña Díaz, Paola Sánchez-Ramos et al.· Gaceta Médica de México· 0 citations
Insulin is an endocrine peptide hormone involved in various physiological processes such as glucose uptake, lipid metabolism, cell growth and repair. Insulin resistance (IR) contributes to different biochemical abnormalities including inflammation, obesity, and prediabetes. IR is a condition associated with impairments...
Priyanka Aswal, S. Setya, Nitish Singh Jangwan et al.· Vietnam Journal of Science a...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.